AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33082178
Drug: Tailored letter
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored letter incorporating patient's screening test results and treatment algorithms sent to family physician
Trial: 32616329
Drug: DAPT with
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT with clopidogrel and aspirin
Trial: 34383540
Drug: Metacognitive interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive interpersonal therapy-group (MIT-G)
Trial: 34383540
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) + waiting list
Trial: 32990231
Drug: Straumann implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straumann implant
Trial: 32959223
Drug: Ceratonia siliqua
RxNorm normalized name: CERATONIA SILIQUA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceratonia siliqua (carob) syrup twice a day for 3 months
Trial: 32959223
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 100 mg twice a day for 3 months
Trial: 32943404
Drug: Methylprednisolone pulse
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulse (intravenous injection, 250 mg·day‐1 for 3 days)
Trial: 33473021
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron dextran
Trial: 614284972
Drug: Smartphone application-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application-delivered notched music therapy and Ginkgo biloba for 3 months
Trial: 32956506
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (20 ml 2% lidocaine + 10 ml 8.4% sodium bicarbonate)
Trial: 32956506
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (20 ml 2% lidocaine + 10 ml 0.9% saline solution)
Trial: 36089595
Drug: diacerein (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein (50mg twice daily)
Trial: 32579779
Drug: Preoperative ultrasound
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative ultrasound guided parasternal block with 0.25% bupivacaine (4 mL into anterior intercostal spaces)
Trial: 32579779
Drug: Postoperative parasternal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative parasternal intercostal block with 0.25% bupivacaine (4 mL into anterior intercostal spaces)
Trial: 35760338
Drug: CPT‐SMART (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐SMART (Cognitive Processing Therapy for PTSD, smoking cessation counseling, pharmacotherapy, and contingency management)
Trial: 35598084
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.2% Ropivacaine with dexamethasone 8 mg (Group R + D)
Trial: 35598084
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.2% Ropivacaine (Group R)
Trial: 33721441
Drug: Nimotuzumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab + PF induction chemotherapy (NPF group)
Trial: 33721441
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy (TPF group)
Trial: 33727509
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch (10 mg over 24 h, with a second patch after 1 h if contractions persisted)
Trial: 33727509
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (20 mg loading dose, followed by 10 mg thrice daily if contractions suppressed)
Trial: 33727509
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch
Trial: 35662230
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy (not specified dosage or duration)
Trial: 33120078
Drug: Compound 34
RxNorm normalized name: Enflurane 99.9% Inhalation Solution [COMPOUND 347]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 34 (naphthyridinone scaffold)
Trial: 32138765
Drug: Vitamin D/calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D/calcium milk fortification and periodontal therapy
Trial: 35649707
Drug: HEAVY (high-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEAVY (high-load strengthening exercise, supervised twice/week)
Trial: 34608631
Drug: Efgartigimod 10
RxNorm normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Efgartigimod 10 mg/kg
Trial: 33249347
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group received constant TENS over the hamstring muscles during exercises.
Trial: 35219521
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (HTV) ventilation (>10 mL/kg predicted body weight)
Trial: 35219521
Drug: Non-high tidal
RxNorm normalized name: marine non-gelling gelatin, high MW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-high tidal volume (non-HTV) ventilation (≤10 mL/kg predicted body weight)
Trial: 37026551
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg/d
Trial: 32228343
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 500 mg/day for 6 months after LSG
Trial: 32228343
Drug: No UDCA
RxNorm normalized name: ,no-udca
DrugBank: NCX-1000 (DB16026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No UDCA treatment (pre-2015 protocol)
Trial: 33790084
Drug: Drug-containing foam
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-containing foam formulations (benzydamine, dexamethasone, allopurinol, rebamipide) prepared with 1–4% SM‐4
Trial: 33269838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 'kidney three-needle' therapy and fire needling therapy
Trial: 32651141
Drug: 0.75 g
RxNorm normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g ZM in 10 mL oxymel
Trial: 32651141
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g ZM in 10 mL oxymel
Trial: 32651141
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of oxymel
Trial: 35365594
Drug: MK-7 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 (200 mcg/day)
Trial: 33974018
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy (co-trimoxazole or doxycycline)
Trial: 34029448
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) glucagon infusion (25 ng/kg/min)
Trial: 34029448
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) glucagon infusion (12.5 ng/kg/min)
Trial: 33144331
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg [14C]lemborexant (100 µCi)
Trial: 34092191
Drug: Beta-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (6.4 g·day‐1 for 28 days)
Trial: 34868479
Drug: Unguided online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided online cognitive-behavioral therapy (CBT)
Trial: 34868479
Drug: Guided online
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided online cognitive-behavioral therapy (CBT)
Trial: 33528893
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg/day for 13 weeks
Trial: 35457330
Drug: L-arginine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (8 gr daily for 8 days)
Trial: 35457330
Drug: L-citrulline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline (8 gr daily for 8 days)
Trial: 35457330
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 gr daily for 8 days)
Trial: 35457330
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (L-arginine, L-citrulline, and placebo)
Trial: 32320566
Drug: Control (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (investigator's choice of therapy)
Trial: 33942343
Drug: Single-injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection of 10 mg nalbuphine
Trial: 33942343
Drug: PCA-mimic method
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA-mimic method of 10 mg nalbuphine (2 mg once for five times with a 30-min interval)
Trial: 34504336
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (500 ml)
Trial: 36167537
Drug: Incremental hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental hemodialysis (twice-weekly for 6 weeks followed by thrice-weekly)
Trial: 36167537
Drug: Conventional hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hemodialysis (thrice-weekly)
Trial: 34256795
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor rehabilitation (1 pre-rehabilitation session and 9 to 12 sessions including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe)
Trial: 33468271
Drug: Freeze-dried strawberry
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried strawberry (24 g/d for 90 days)
Trial: 32428636
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy
Trial: 35709650
Drug: Metformin Glycinate
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metformin Glycinate (MG) treatment
Trial: 34256828
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support intervention (DESI) for primary endocrine therapy (PET) or surgery with adjuvant therapies
Trial: 34256828
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support intervention (DESI) for adjuvant chemotherapy after surgery
Trial: 35894958
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 3 mg/kg body mass
Trial: 36350066
Drug: Phone-delivered CBT
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone-delivered CBT (6, 8, or 12 weekly sessions) augmented with a CBT skills practice smartphone application
Trial: 36350066
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) T2DM care
Trial: 34997360
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + thermosensitive gel containing 0.8% oligo hyaluronic acid and octenidine HCl 0.625%
Trial: 35975643
Drug: 0.247% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.247% ropivacaine in 20 mL for ACB and IPACK block
Trial: 33511604
Drug: Standard emergency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard emergency room treatment
Trial: 33511604
Drug: Standard ambulance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ambulance and hospital treatment
Trial: 33367229
Drug: DMPA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA administration in the 12-14 mm group
Trial: 33367229
Drug: DMPA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA administration in the 15-17 mm group
Trial: 33367229
Drug: DMPA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA administration in the ≥ 18 mm group
Trial: 33367229
Drug: 24-h MPA
RxNorm normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h MPA concentrations post-DMPA administration
Trial: 35759476
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavioural therapy (CBT) plus social participation program
Trial: 32567233
Drug: Oxycodone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone combined with flurbiprofen axetil (OF)
Trial: 36073583
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy (standard treatment + cell therapy)
Trial: 36073583
Drug: Endoscopic surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic surgical treatment
Trial: 34910859
Drug: NVX‐CoV2373 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX‐CoV2373 vaccine
Trial: 32366273
Drug: CTTS monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CTTS monthly calls
Trial: 33165918
Drug: Atropine 0.5
RxNorm normalized name: homatropine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.5 mg (Group A)
Trial: 35103539
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus 3cir‐OFF HAIC (400 mg sorafenib twice daily + 35 mg/m2 oxaliplatin followed by 600 mg/m2 5‐fluorouracil, days 1‐3)
Trial: 35103539
Drug: Sorafenib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib alone (400 mg twice daily)
Trial: 34563982
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose aspirin (LDA) 60 mg
Trial: 33338437
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg every other day for 12 weeks
Trial: 36450449
Drug: Tumour necrosis
RxNorm normalized name: Tumour necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour necrosis factor (TNF) inhibitor (TNFi)
Trial: 38915065
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (sulfasalazine and hydroxychloroquine)
Trial: 36450449
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (TNFi and triple therapy)
Trial: 34314856
Drug: MTM +
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MTM + 12 months of telehealth‐delivered medical nutrition therapy (tele‐MNT)
Trial: 33185896
Drug: Indomethacin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (1.2 mg kg–1 oral dose)
Trial: 34622548
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (3, 7 or 14 mg)
Trial: 34622548
Drug: Comparator (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (placebo or once‐daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once‐weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10])
Trial: 36030327
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron followed by daily doses for five days
Trial: 33652093
Drug: Hospice representatives
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hospice representatives reporting on medication shortages
Trial: 33652093
Drug: Hospice representatives
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hospice representatives reporting on missing opioid medications
Trial: 35588970
Drug: Rapid phenotypic
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programmes (ASP)
Trial: 34914696
Drug: 3HP facilitated
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP facilitated directly observed therapy (DOT)
Trial: 34914696
Drug: 3HP facilitated
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP facilitated self-administered therapy (SAT)
Trial: 35177302
Drug: mRNA-1273 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (100 µg, two doses, intramuscular injections 28 days apart)
Trial: 33766713
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα biomarker
Trial: 33766713
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα and emmprin biomarkers
Trial: 33766713
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα, survivin, or BCL‐2 biomarkers
Trial: 33766713
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant chemotherapy (no-NAC)
Trial: 33204076
Drug: XueBiJing (XBJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing (XBJ) injection, 100 mL, q 12 h for 5-7 days
Trial: 33139537
Drug: Subcutaneous BFKB8488A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous BFKB8488A injection
Trial: 34417396
Drug: 40U DaxibotulinumtoxinA
RxNorm normalized name: daxibotulinumtoxinA-lanm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40U DaxibotulinumtoxinA (DAXI) treatment
Trial: 35953872
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous cefazolin (1 g)
Trial: 33340496
Drug: Inert auricular
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert auricular placebo patches
Trial: 35104873
Drug: Analytical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analytical treatment interruptions (ATI)
Trial: 33407719
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine plus ketamine (ketodex)
Trial: 32687804
Drug: BPZE1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPZE1 vaccine (107, 108, and 109 CFU doses)
Trial: 32687804
Drug: BPZE1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPZE1 vaccine (all doses)
Trial: 32051822
Drug: 4 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 treatment sessions (group A)
Trial: 32051822
Drug: 8 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 treatment sessions (group B)
Trial: 32051822
Drug: 12 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 treatment sessions (group C)
Trial: 35299115
Drug: Dietary carob
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary carob fruit (CF) supplementation (1 g/kg diet)
Trial: 35299115
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 g/kg diet)